Related Experiment Video
Updated: Jan 2, 2026

Isolating Mesangiogenic Progenitor Cells MPCs from Human Bone Marrow
Published on: July 15, 2016
Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma
Simone Pacini1, Marina Montali1, Francesco Mazziotta2
1Department of Clinical and Experimental Medicine, Hematology Division, University of Pisa, Pisa, Italy.
Abstract:
Multiple myeloma (MM) progresses mainly in the bone marrow where the involvement of a specific microenvironment plays a critical role in maintaining plasma cell growth, spread, and survival. In active disease, the switch from a pre-vascular/non-active phase to a vascular phase is coupled with the impairment of bone turnover. Previously, we have isolated Mesangiogenic Progenitor Cells (MPCs), a bone marrow population that showed mesengenic and angiogenic potential, both in vitro and in vivo. MPC differentiation into musculoskeletal tissue and their ability of sprouting angiogenesis are mutually exclusive, suggesting a role in the imbalancing of the microenvironment in multiple myeloma. MPCs from 32 bone marrow samples of multiple myeloma and 23 non-hematological patients were compared in terms of frequency, phenotype, mesengenic/angiogenic potential, and gene expression profile. Defective osteogenesis was recorded for MM-derived MPCs that showed longer angiogenic sprouting distances respect to non-hematological MPCs, retaining this capability after mesengenic induction. This altered MPCs differentiation potential was not detected in asymptomatic myelomatous disease. These in vitro experiments are suggestive of a forced angiogenic fate in MPCs isolated from MM patients, which also showed increased sprouting activity. Taking together our results suggest a possible role of these cells in the "angiogenic switch" in the MM micro-environment.
Insights
Mesangiogenic progenitor cells (MPCs) from multiple myeloma patients show defective bone formation and enhanced blood vessel growth. These findings suggest MPCs may drive the "angiogenic switch" crucial for multiple myeloma progression.
Area of Science:
- Hematology
- Oncology
- Stem Cell Biology
Background:
- Multiple myeloma (MM) bone marrow microenvironment is critical for disease progression.
- MM involves a shift from impaired bone turnover to a vascular phase.
- Mesangiogenic progenitor cells (MPCs) possess both mesengenic and angiogenic potential.
Purpose of the Study:
- To investigate the role of MPCs in the MM microenvironment.
- To compare MPCs from MM patients and non-hematological controls.
- To determine if MPCs contribute to the MM-associated "angiogenic switch".
Main Methods:
- Isolated and characterized MPCs from bone marrow samples of MM patients and controls.
- Assessed MPC frequency, phenotype, mesengenic/angiogenic potential, and gene expression.
- Compared osteogenesis and angiogenesis capabilities of MM-derived MPCs versus controls.
Main Results:
- MM-derived MPCs exhibited defective osteogenesis compared to controls.
- MM-derived MPCs showed significantly increased angiogenic sprouting.
- This altered differentiation potential was specific to active MM, not asymptomatic disease.
- MPCs retained angiogenic potential even after attempted mesengenic induction.
Conclusions:
- MPCs from MM patients display a bias towards an angiogenic fate.
- This altered MPC behavior may contribute to the
- angiogenic switch
- in the MM microenvironment.
- MPCs represent a potential therapeutic target for modulating MM progression.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Production of Formed Elements
Most HSCs commit to...
Mechanism of Angiogenesis
Mesenchymal Stem Cells
Regulation of Angiogenesis and Blood Supply
Lineage Commitment

